Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
60.35
-0.39 (-0.64%)
Official Closing Price
Updated: 4:10 PM EST, Feb 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
12,873,818
Open
60.85
Bid (Size)
60.22 (400)
Ask (Size)
60.80 (200)
Prev. Close
60.74
Today's Range
59.48 - 61.30
52wk Range
42.52 - 63.33
Shares Outstanding
2,222,113,553
Dividend Yield
4.18%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Today 6:59 EST
From
Bristol Myers Squibb
Via
Business Wire
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
February 16, 2026
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...
Via
MarketMinute
Topics
Intellectual Property
Performance
YTD
+12.9%
+12.9%
1 Month
+11.3%
+11.3%
3 Month
+28.9%
+28.9%
6 Month
+25.2%
+25.2%
1 Year
+10.9%
+10.9%
More News
Read More
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
February 12, 2026
Via
StockStory
Topics
Earnings
Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook
↗
February 05, 2026
Via
Chartmill
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
February 11, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
February 10, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout
↗
January 28, 2026
Via
Chartmill
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
February 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus
February 06, 2026
Via
StockStory
Why Bristol Myers Squibb Stock Topped the Market Today
↗
February 05, 2026
Via
The Motley Fool
Bristol Myers (BMY) Q4 2025 Earnings Transcript
↗
February 05, 2026
Via
The Motley Fool
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025
February 05, 2026
Via
StockStory
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
February 05, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
February 04, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Q4 Earnings Preview: Profits Under Pressure Even As Wall Street Bets On 2026 Pipeline
↗
February 04, 2026
Via
Stocktwits
Topics
Artificial Intelligence
Intellectual Property
Workforce
Bristol-Myers Squibb Earnings: What To Look For From BMY
February 03, 2026
Via
StockStory
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
February 03, 2026
From
Bristol Myers Squibb
Via
Business Wire
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
February 02, 2026
Via
MarketMinute
Topics
Economy
Government
Intellectual Property
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
February 02, 2026
Via
MarketMinute
Topics
ETFs
Government
Initial Public Offering
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year
↗
January 30, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
World Trade
3 Unpopular Stocks That Concern Us
January 28, 2026
Via
StockStory
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
January 26, 2026
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
January 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
↗
January 24, 2026
Via
The Motley Fool
Topics
ETFs
Intellectual Property
World Trade
Frequently Asked Questions
Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 60.35
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 02/17/26 04:10 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 134.10B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 134B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.